Biotechnology - Cell Therapy & Regenerative Medicine
Strategic Profile
With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges. Pluri is a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures.
Cyborg Score Rationale
The company generated $1.3M in revenue over the trailing twelve months with -$22.2M operating income and a -1659.9% operating margin. However, strong IP positioning and active partnerships demonstrate strategic momentum despite early-stage commercialization challenges.
Top Insights
China's CNIPA granted a patent covering proprietary 3D immune cell expansion and activation technology (February 2026).
Pluri completed the first phase of its PluriCDMO program with Resbiomed in January 2026 for placenta-derived collagen-rich biomaterials.
Chairman Alejandro Weinstein invested an additional $2.5 million at a 30% premium to market price in March 2026.
Diversified revenue model spanning regenerative medicine, foodtech, agtech, and CDMO services reduces single-market dependency.
Named Competitors
Lyell Immunopharma — Cell-based immunotherapy development
Brainstorm Cell Therapeutics — Cell therapy for neurological conditions
Lineage Cell Therapeutics — Cell-based regenerative medicine
Recent Developments
(May 2026) SEC filing submitted on May 14, 2026
(March 2026) Chairman invested additional $2.5 million in company at 30% premium
(February 2026) Secured China patent for 3D immune cell expansion technology
(January 2026) Completed first phase of Resbiomed collaboration for placenta-derived biomaterials
Open the full interactive Pluri Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.